National Imaging Associates, Inc.*	
Clinical guidelines BRAIN PET SCAN	Original Date: July 1999
CPT Codes: 78608, 78609	Last Revised Date: May 2~~June 20~~22~~1~~
Guideline Number: NIA_CG_071	Implementation Date: January 202~~3~~2

INDICATIONS FOR BRAIN PET SCAN ~~using FDG (Fluorodeoxyglucose)[1-5]~~
~~(Albano, 2018; de-Bonilla-Damiá, 2017; Jones, 2016; Lewitschnig, 2013; Maza, 2013)~~

Known brain tumor or cancer
- To differentiate radiation necrosis or post-treatment change from residual/recurrent tumor ~~on~~ **when** brain **MRI[‡ 1] is inconclusive** ~~(NCCN, 2020)~~
- To differentiate low from high grade glioma when brain **MRI[‡]** is inconclusive[2, 3] ~~(Dunet, 2016; Verger, 2017)~~
- **For evaluation of primary brain lymphoma when brain MRI[‡] is inconclusive**[4]
- For evaluation ~~of primary brain lymphoma~~**evaluation of meningiomas** when brain **MRI[‡]** is inconclusive[4, 5]
- To guide intervention/biopsy

To determine operability of refractory seizures[6-8]
~~(Govil-Dalela, 2018; Jones, 2016; Tang, 2019)~~

Post-treatment/procedural evaluation
- A follow-up study may be needed to help evaluate a patient's progress after treatment, procedure, intervention, or surgery. Documentation requires a medical reason that clearly indicates why additional imaging is needed.
-

Mild Cognitive Impairment or Dementia[9]
~~(Motara, 2017)~~
- For the detection of early Alzheimer's disease†;
- For the differentiation between Alzheimer's disease, ~~d~~**D**ementia with Lewy body disease (DLB) and ~~f~~**F**rontotemporal lobar degeneration (FTD)†; or
- To assess for the presence of **b**~~B~~eta amyloid plaque in Alzheimer's disease when being considered

---

* National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

for Aduhelm treatment†

†Note: **AFTER** an initial insufficient evaluation with a Brain **MRI‡** and the following 2 criteria have been met[10, 11] ~~(ACR, 2015; Bohnen, 2011)~~:

- Objective cognitive impairment[12, 13] ~~(Albert, 2011; Iaccarino, 2017)~~ has been demonstrated by:
    - Either by Mini Mental Status Evaluation (MMSE) or Montreal Cognitive Assessment (MoCA) less than 26[14] ~~(Davis, 2015)~~
    - **OR** by Neuropsychological testing showing at least mild cognitive impairment[15, 16] ~~(Caminiti, 2018; Inui, 2017)~~
- Potential treatable causes have been assessed and addressed ~~(Albert, 2011)~~,[12] such as:
    - Metabolic causes, such as thyroid or vitamin deficiency, anemia, or toxic metabolic encephalopathy
    - Medication side effects[17] ~~(Campbell, 2010)~~
    - Medical causes, such as vascular or traumatic or inflammatory

‡**Note:** Brain CT is acceptable if brain MRI is contraindicated. However, Brain CT cannot be substituted for MRI when Brain PET is requested for evaluation of amyloid plaque because MRI is a prerequisite to Aduhelm treatment.

BACKGROUND

Positron Emission Tomography (PET) scanning ~~using FDG (fluorodeoxyglucose)~~**can be used to** assesses brain metabolism and perfusion. Uses include identifying epileptic foci prior to surgery, differentiation of residual tumor versus scar, **helping differentiate inconclusive findings on Brain MRI** and **identifying** causes of cognitive decline ~~(Wippold, 2015)~~.[18]

~~Current agents which show promise in assessing plaques of the protein beta-amyloid include: florbetapir F 18, florbetaben F 18, and flutemetamol F 18 with PET. PET/MR is also being studied (Zhang, 2017).[21] Other new agents target the tau protein and microglial activation.~~

POLICY HISTORY

Date	Summary
May ~~July~~ **2022**	• **Updated references and background** • **Removed FDG from Indications title** • **Added meningioma when MR is inconclusive**
July 2021	• Added information on detection of amyloid for use with Aduhelm
May 2020	• Added CNS lymphoma and glioma after inconclusive imaging • For the detection of early Alzheimer's disease or the differentiation between Alzheimer's disease, Dementia with Lewy body disease (DLB) versus Frontotemporal lobar degeneration (FTD) after appropriate clinical work up and initial insufficient evaluation with a brain MRI • Changed post-surgery to post treatment • Removed longitudinal assessment of memory decline

	• Added references
June 2019	• Changed indications title to specify: 'using FDG (fluourodeoxyglucose)' • For indication: Mild Cognitive Impairment or Dementia, added '*Brain MRI to rule out structural causes or Brain CT if MRI is contraindicated*' • Added information to background section

REFERENCES

Albano D, Bosio G, Bertoli M, et al. 18F-FDG PET/CT in primary brain lymphoma. *J Neurooncol*. 2018; 136(3):577-583. doi:10.1007/s11060-017-2686-3.

Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. May 2011; 7(3):270-279.

American College of Radiology (ACR). ACR Appropriateness Criteria®. https://acsearch.acr.org/list. Published 2017.

American College of Radiology (ACR). ACR-ASNR Practice Parameter for Brain PET/CT Imaging in Dementia. 2015.

American College of Radiology (ACR). ACR Appropriateness Criteria®. Seizures and epilepsy. 2014.

Bashir U, Mallia A, Stirling J, et al. PET/MRI in oncological imaging: State of the art. *Diagnostics*. 2015; 5:333-357.

Bohnen NI, Djang DS, Herholz K, et al. Effectiveness and Safety of ^{18}F-FDG PET in the Evaluation of dementia: A review of the recent literature. J Nuc Med. 2012 Jan 1; 53(1):59-71. Epub 2011 Dec 15.

Caminiti SP, Ballarini T, Sala A, et al. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. *Neuroimage Clin*. 2018;18:167-177. doi:10.1016/j.nicl.2018.01.019.

Campbell NL, Boustani MA, Lane KA, et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. *Neurology*. 2010; 75(2):152.

Davis DH, Creavin ST, Yip JL, et al. Montreal Cognitive Assessment for the diagnosis of Alzheimer's disease and other dementias. *Cochrane Database Syst Rev*. 2015.

De-Bonilla-Damiá Á, Fernández-López R, Capote-Huelva FJ, et al. Role of ^{18}F-FDG PET/CT in primary brain lymphoma. Utilidad de la ^{18}F-FDG PET/TC en el linfoma cerebral primario. *Rev Esp Med Nucl Imagen Mol*. 2017; 36(5):298-303.

Duerden EG, Albanese MC. Localization of pain-related brain activation: a meta-analysis of neuroimaging data. *Human Brain Mapping*. 2013; 34(1):109-49. doi: 10.1002/hbm.21416.

Dunet V, Pomoni A, Hottinger A, et al. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: Systematic review and meta-analysis. *Neuro-Oncology*. 2016 Mar; 18(3):426-34.

Govil-Dalela T, Kumar A, Behen ME, Chugani HT, Juhász C. Evolution of lobar abnormalities of cerebral glucose metabolism in 41 children with drug-resistant epilepsy. *Epilepsia*. 2018;59(7):1307-1315. doi:10.1111/epi.14404.

Grinenko O, Li J, Mosher JC, et al. A fingerprint of the epileptogenic zone in human epilepsies. *Brain*. 2018 Jan 1; 141(1):117-131.

Heiss W, Raab P, Lanfermann H. Multimodality assessment of brain tumors and tumor recurrence. *J Nucl Med*. October 2011; 52:1585-1600.

Iaccarino L, Sala A, Caminiti SP, et al. The emerging role of PET imaging in dementia. *F1000Res*. 2017; 6:1830.

Inui Y, Ito K, Kato T, SEAD-J Study Group. Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study. *J Alzheimers Dis*. 2017;60(3):877-887. doi:10.3233/JAD-170395.

Ishii K. PET Approaches for diagnosis of dementia. *AJNR Am J Neuroradiol*. 2014 Nov; 35(11):2030-38.

Jones AL, Cascino GD. Evidence on use of neuroimaging for surgical treatment of temporal lobe epilepsy: A systematic review. *JAMA Neurol*. April 2016; 73(4):464-470.

Kawai N, Miyake K, Okada M, Yamamoto Y, Nishiyama Y, Tamiya T. *No Shinkei Geka*. 2013; 41(2):117-126.

Lewitschnig S, Gedela K, Toby M, et al. ^{18}F-FDG PET/CT in HIV-related central nervous system pathology. *Eur J Nucl Med Mol Imaging*. 2013; 40(9):1420-1427. doi:10.1007/s00259-013-2448-1.

Maza S, Buchert R, Brenner W, et al. Brain and whole-body FDG-PET in diagnosis, treatment monitoring and long-term follow-up of primary CNS lymphoma. Radiol Oncol. 2013; 47(2):103-110. Published 2013 May 21. doi:10.2478/raon-2013-0016.

Motara H, Olusoga T, Russell G, et al. Clinical impact and diagnostic accuracy of 2-[18F]-fluoro-2-deoxy-d-glucose positron-emission tomography/computed tomography (PET/CT) brain imaging in patients with cognitive impairment: A tertiary centre experience in the UK. *Clin Radiol*. 2017; 72(1):63-73. doi:10.1016/j.crad.2016.08.003.

National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. 2020. https://www.nccn.org/professionals/imaging/content.

Singhal T. Positron emission tomography applications in clinical neurology. *Semin Neurol*. 2012; 32(4):421-31. doi: 10.1055/s-0032-1331813.

Sperling RA, Johnson KA, Reiman EM, et al. Alzheimer's Plaques in PET Brain Scans Identify Future Cognitive Decline. *Science Daily*. 2012.

Steriade C, Martins W, Bulacio J, et al. Localization yield and seizure outcome in patients undergoing bilateral SEEG exploration. *Epilepsia*. 2019 Jan; 60(1):107-120.

Tang Y, Liow JS, Zhang Z, et al. The Evaluation of Dynamic FDG-PET for Detecting Epileptic Foci and Analyzing Reduced Glucose Phosphorylation in Refractory Epilepsy. Front Neurosci. 2019; 12:993. Published 2019 Jan 9. doi:10.3389/fnins.2018.00993.

Verger A, Langen KJ. PET Imaging in Glioblastoma: Use in Clinical Practice. In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 9. Available from: https://www.ncbi.nlm.nih.gov/books/NBK469986/ doi: 10.15586/codon.glioblastoma.2017.ch9.

Widjaja E, Raybaud C. Advances in neuroimaging in patients with epilepsy. *Neurosurg Focus*. 2008; 25(3):E3.

Wippold FJ 2nd, Brown DC, Broderick DF, et al. ACR Appropriateness Criteria®. Dementia and movement disorders. *J Am Coll Radiol*. 2015 Jan; 12(1):19-28.

Zhang XY, Yang Zl, Lu GM, et al. PET/MR imaging: New frontier in Alzheimer's disease and other dementias. *Front Mol Neurosci*. 2017 Nov 1; 10:343.

Reviewed / Approved by NIA Clinical Guideline Committee

1. NCCN Imaging Appropriate Use Criteria™. National Comprehensive Cancer Network (NCCN). Updated 2021. Accessed November 4, 2021. https://www.nccn.org/professionals/imaging/default.aspx

2. Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. *Neuro Oncol*. Mar 2016;18(3):426-34. doi:10.1093/neuonc/nov148

3. Verger A, Langen KJ. PET Imaging in Glioblastoma: Use in Clinical Practice. In: De Vleeschouwer S, ed. *Glioblastoma*. Codon Publications; 2017.

4. Verger A, Kas A, Darcourt J, Guedj E. PET Imaging in Neuro-Oncology: An Update and Overview of a Rapidly Growing Area. *Cancers (Basel)*. Feb 22 2022;14(5)doi:10.3390/cancers14051103

5. Rachinger W, Stoecklein VM, Terpolilli NA, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. *J Nucl Med*. Mar 2015;56(3):347-53. doi:10.2967/jnumed.114.149120

6. Govil-Dalela T, Kumar A, Behen ME, Chugani HT, Juhász C. Evolution of lobar abnormalities of cerebral glucose metabolism in 41 children with drug-resistant epilepsy. *Epilepsia*. Jul 2018;59(7):1307-1315. doi:10.1111/epi.14404

7. Jones AL, Cascino GD. Evidence on Use of Neuroimaging for Surgical Treatment of Temporal Lobe Epilepsy: A Systematic Review. *JAMA Neurol*. Apr 2016;73(4):464-70. doi:10.1001/jamaneurol.2015.4996

8. Tang Y, Liow JS, Zhang Z, et al. The Evaluation of Dynamic FDG-PET for Detecting Epileptic Foci and Analyzing Reduced Glucose Phosphorylation in Refractory Epilepsy. *Front Neurosci*. 2018;12:993. doi:10.3389/fnins.2018.00993

9. Motara H, Olusoga T, Russell G, et al. Clinical impact and diagnostic accuracy of 2-[(18)F]-fluoro-2-deoxy-d-glucose positron-emission tomography/computed tomography (PET/CT) brain imaging in

patients with cognitive impairment: a tertiary centre experience in the UK. *Clin Radiol*. Jan 2017;72(1):63-73. doi:10.1016/j.crad.2016.08.003

10. Frey KA, Lodge MA, Meltzer CC, et al. ACR-ASNR Practice Parameter for Brain PET/CT Imaging Dementia. *Clin Nucl Med*. Feb 2016;41(2):118-25. doi:10.1097/rlu.0000000000001037

11. Bohnen NI, Djang DS, Herholz K, Anzai Y, Minoshima S. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. *J Nucl Med*. Jan 2012;53(1):59-71. doi:10.2967/jnumed.111.096578

12. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. May 2011;7(3):270-9. doi:10.1016/j.jalz.2011.03.008

13. Iaccarino L, Sala A, Caminiti SP, Perani D. The emerging role of PET imaging in dementia. *F1000Res*. 2017;6:1830. doi:10.12688/f1000research.11603.1

14. Davis DH, Creavin ST, Yip JL, Noel-Storr AH, Brayne C, Cullum S. Montreal Cognitive Assessment for the diagnosis of Alzheimer's disease and other dementias. *Cochrane Database Syst Rev*. Oct 29 2015;2015(10):Cd010775. doi:10.1002/14651858.CD010775.pub2

15. Caminiti SP, Ballarini T, Sala A, et al. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. *Neuroimage Clin*. 2018;18:167-177. doi:10.1016/j.nicl.2018.01.019

16. Inui Y, Ito K, Kato T. Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study. *J Alzheimers Dis*. 2017;60(3):877-887. doi:10.3233/jad-170395

17. Campbell NL, Boustani MA, Lane KA, et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. *Neurology*. Jul 13 2010;75(2):152-9. doi:10.1212/WNL.0b013e3181e7f2ab

18. Wippold FJ, 2nd, Brown DC, Broderick DF, et al. ACR Appropriateness Criteria Dementia and Movement Disorders. *J Am Coll Radiol*. Jan 2015;12(1):19-28. doi:10.1016/j.jacr.2014.09.025

ADDITIONAL RESOURCES

1. American College of Radiology. ACR Appropriateness Criteria® Seizures and Epilepsy. American College of Radiology. Updated 2019. Accessed November 2, 2021. https://acsearch.acr.org/docs/69479/Narrative/

2. Bashir U, Mallia A, Stirling J, et al. PET/MRI in Oncological Imaging: State of the Art. *Diagnostics (Basel)*. Jul 21 2015;5(3):333-57. doi:10.3390/diagnostics5030333

3. Duerden EG, Albanese MC. Localization of pain-related brain activation: a meta-analysis of neuroimaging data. *Hum Brain Mapp*. Jan 2013;34(1):109-49. doi:10.1002/hbm.21416

4. Grinenko O, Li J, Mosher JC, et al. A fingerprint of the epileptogenic zone in human epilepsies. *Brain*. Jan 1 2018;141(1):117-131. doi:10.1093/brain/awx306

5. Heiss WD, Raab P, Lanfermann H. Multimodality assessment of brain tumors and tumor recurrence. *J Nucl Med*. Oct 2011;52(10):1585-600. doi:10.2967/jnumed.110.084210

6. Ishii K. PET approaches for diagnosis of dementia. *AJNR Am J Neuroradiol*. Nov-Dec 2014;35(11):2030-8. doi:10.3174/ajnr.A3695

7. Kawai N, Miyake K, Okada M, Yamamoto Y, Nishiyama Y, Tamiya T. [Usefulness and limitation of FDG-PET in the diagnosis of primary central nervous system lymphoma]. *No Shinkei Geka*. Feb 2013;41(2):117-26.

8. Singhal T. Positron emission tomography applications in clinical neurology. *Semin Neurol*. Sep 2012;32(4):421-31. doi:10.1055/s-0032-1331813

9. Steriade C, Martins W, Bulacio J, et al. Localization yield and seizure outcome in patients undergoing bilateral SEEG exploration. *Epilepsia*. Jan 2019;60(1):107-120. doi:10.1111/epi.14624

10. Widjaja E, Raybaud C. Advances in neuroimaging in patients with epilepsy. *Neurosurg Focus*. Sep 2008;25(3):E3. doi:10.3171/foc/2008/25/9/e3

1. Albert NL, Weller M, Suchorska B, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. *Neuro Oncol*. Sep 2016;18(9):1199-208. doi:10.1093/neuonc/now058

1. NCCN Imaging Appropriate Use Criteria™. National Comprehensive Cancer Network (NCCN). Updated 2021. Accessed November 4, 2021. https://www.nccn.org/professionals/imaging/default.aspx

2. Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. *Neuro Oncol*. Mar 2016;18(3):426-34. doi:10.1093/neuonc/nov148

3. Verger A, Langen KJ. PET Imaging in Glioblastoma: Use in Clinical Practice. In: De Vleeschouwer S, ed. *Glioblastoma*. Codon Publications; 2017.

4. Verger A, Kas A, Darcourt J, Guedj E. PET Imaging in Neuro-Oncology: An Update and Overview of a Rapidly Growing Area. *Cancers (Basel)*. Feb 22 2022;14(5)doi:10.3390/cancers14051103

5. Rachinger W, Stoecklein VM, Terpolilli NA, et al. Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue. *J Nucl Med*. Mar 2015;56(3):347-53. doi:10.2967/jnumed.114.149120

6. Govil-Dalela T, Kumar A, Behen ME, Chugani HT, Juhász C. Evolution of lobar abnormalities of cerebral glucose metabolism in 41 children with drug-resistant epilepsy. *Epilepsia*. Jul 2018;59(7):1307-1315. doi:10.1111/epi.14404

7. Jones AL, Cascino GD. Evidence on Use of Neuroimaging for Surgical Treatment of Temporal Lobe Epilepsy: A Systematic Review. *JAMA Neurol*. Apr 2016;73(4):464-70. doi:10.1001/jamaneurol.2015.4996

8. Tang Y, Liow JS, Zhang Z, et al. The Evaluation of Dynamic FDG-PET for Detecting Epileptic Foci and Analyzing Reduced Glucose Phosphorylation in Refractory Epilepsy. *Front Neurosci*. 2018;12:993. doi:10.3389/fnins.2018.00993

9. Motara H, Olusoga T, Russell G, et al. Clinical impact and diagnostic accuracy of 2-[(18)F]-fluoro-2-deoxy-d-glucose positron-emission tomography/computed tomography (PET/CT) brain imaging in patients with cognitive impairment: a tertiary centre experience in the UK. *Clin Radiol*. Jan 2017;72(1):63-73. doi:10.1016/j.crad.2016.08.003

10. Frey KA, Lodge MA, Meltzer CC, et al. ACR-ASNR Practice Parameter for Brain PET/CT Imaging Dementia. *Clin Nucl Med*. Feb 2016;41(2):118-25. doi:10.1097/rlu.0000000000001037

11. Bohnen NI, Djang DS, Herholz K, Anzai Y, Minoshima S. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. *J Nucl Med*. Jan 2012;53(1):59-71. doi:10.2967/jnumed.111.096578

12. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. May 2011;7(3):270-9. doi:10.1016/j.jalz.2011.03.008

13. Iaccarino L, Sala A, Caminiti SP, Perani D. The emerging role of PET imaging in dementia. *F1000Res*. 2017;6:1830. doi:10.12688/f1000research.11603.1

14. Davis DH, Creavin ST, Yip JL, Noel-Storr AH, Brayne C, Cullum S. Montreal Cognitive Assessment for the diagnosis of Alzheimer's disease and other dementias. *Cochrane Database Syst Rev*. Oct 29 2015;2015(10):Cd010775. doi:10.1002/14651858.CD010775.pub2

15. Caminiti SP, Ballarini T, Sala A, et al. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort. *Neuroimage Clin*. 2018;18:167-177. doi:10.1016/j.nicl.2018.01.019

16. Inui Y, Ito K, Kato T. Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study. *J Alzheimers Dis*. 2017;60(3):877-887. doi:10.3233/jad-170395

17. Campbell NL, Boustani MA, Lane KA, et al. Use of anticholinergics and the risk of cognitive impairment in an African American population. *Neurology*. Jul 13 2010;75(2):152-9. doi:10.1212/WNL.0b013e3181e7f2ab

18. Wippold FJ, 2nd, Brown DC, Broderick DF, et al. ACR Appropriateness Criteria Dementia and Movement Disorders. *J Am Coll Radiol*. Jan 2015;12(1):19-28. doi:10.1016/j.jacr.2014.09.025

State-Specific Required Language

1. American College of Radiology. ACR Appropriateness Criteria® Seizures and Epilepsy. American College of Radiology. Updated 2019. Accessed November 2, 2021. https://acsearch.acr.org/docs/69479/Narrative/

2. Bashir U, Mallia A, Stirling J, et al. PET/MRI in Oncological Imaging: State of the Art. *Diagnostics (Basel)*. Jul 21 2015;5(3):333-57. doi:10.3390/diagnostics5030333

3. Duerden EG, Albanese MC. Localization of pain-related brain activation: a meta-analysis of neuroimaging data. *Hum Brain Mapp*. Jan 2013;34(1):109-49. doi:10.1002/hbm.21416

4. Grinenko O, Li J, Mosher JC, et al. A fingerprint of the epileptogenic zone in human epilepsies. *Brain*. Jan 1 2018;141(1):117-131. doi:10.1093/brain/awx306

5. Heiss WD, Raab P, Lanfermann H. Multimodality assessment of brain tumors and tumor recurrence. *J Nucl Med*. Oct 2011;52(10):1585-600. doi:10.2967/jnumed.110.084210

6. Ishii K. PET approaches for diagnosis of dementia. *AJNR Am J Neuroradiol*. Nov-Dec 2014;35(11):2030-8. doi:10.3174/ajnr.A3695

7. Kawai N, Miyake K, Okada M, Yamamoto Y, Nishiyama Y, Tamiya T. [Usefulness and limitation of FDG-PET in the diagnosis of primary central nervous system lymphoma]. *No Shinkei Geka*. Feb 2013;41(2):117-26.

8. Singhal T. Positron emission tomography applications in clinical neurology. *Semin Neurol*. Sep 2012;32(4):421-31. doi:10.1055/s-0032-1331813

9. Steriade C, Martins W, Bulacio J, et al. Localization yield and seizure outcome in patients undergoing bilateral SEEG exploration. *Epilepsia*. Jan 2019;60(1):107-120. doi:10.1111/epi.14624

10. Widjaja E, Raybaud C. Advances in neuroimaging in patients with epilepsy. *Neurosurg Focus*. Sep 2008;25(3):E3. doi:10.3171/foc/2008/25/9/e3

GENERAL INFORMATION

It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.